These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 26354056)
1. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome. Lee JH; Ahn SG; Park B; Park SW; Kang YS; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J Korean J Intern Med; 2015 Sep; 30(5):620-8. PubMed ID: 26354056 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060 [TBL] [Abstract][Full Text] [Related]
3. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. Jeong YH; Oh JH; Yoon HJ; Park Y; Suh J; Lee SW; Lee K; Kim JS; Chun WJ; Park YH; Nam CW; Kim JH; Ahn JH; Hwang SJ; Hwang JY; Tantry US; Gurbel PA; Shin ES Thromb Haemost; 2021 Oct; 121(10):1376-1386. PubMed ID: 33401330 [TBL] [Abstract][Full Text] [Related]
5. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415 [TBL] [Abstract][Full Text] [Related]
6. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S; Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558 [TBL] [Abstract][Full Text] [Related]
8. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis. Zhang H; Zhang P; Dong P; Yang X; Wang Y; Zhang H; Yan J; Zhang Y; Zhang T; Li Y Coron Artery Dis; 2017 Nov; 28(7):597-604. PubMed ID: 28968313 [TBL] [Abstract][Full Text] [Related]
9. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985 [TBL] [Abstract][Full Text] [Related]
10. Randomized Comparison of Oral P2Y Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP; Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698 [TBL] [Abstract][Full Text] [Related]
12. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. Jin C; Kim MH; Bang J; Serebruany V Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466 [TBL] [Abstract][Full Text] [Related]
14. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000 [TBL] [Abstract][Full Text] [Related]
15. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
16. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study. Pourdjabbar A; Hibbert B; Chong AY; Le May MR; Labinaz M; Simard T; Ramirez FD; Lugomirski P; Maze R; Froeschl M; Glover C; Dick A; Marquis JF; Bernick J; Wells G; So DY; Thromb Haemost; 2017 Jan; 117(2):303-310. PubMed ID: 27761582 [TBL] [Abstract][Full Text] [Related]
17. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203 [TBL] [Abstract][Full Text] [Related]
18. Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction. Tateishi K; Saito Y; Kitahara H; Nakayama T; Fujimoto Y; Kobayashi Y J Cardiol; 2020 May; 75(5):473-477. PubMed ID: 31718953 [TBL] [Abstract][Full Text] [Related]
19. Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study. Fukase T; Doi S; Dohi T; Koike T; Nishio R; Yasuda H; Takeuchi M; Takahashi N; Chikata Y; Endo H; Nishiyama H; Okai I; Iwata H; Okazaki S; Daida H; Suwa S; Minamino T; Miyauchi K Cardiovasc Drugs Ther; 2024 Oct; 38(5):947-957. PubMed ID: 37097381 [TBL] [Abstract][Full Text] [Related]
20. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction. Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]